Rainbow Rare Earths Limited

Management did not report quarterly revenue or EPS. It reiterated published project economics: Phalaborwa was last modeled in December 2024 using NdPr pricing of $110/kg, with about $181 million of annual EBITDA, circa $320 million of capex, a 16-year life, and a 10% discount-rate NPV assumption; Uberaba was described as having almost $1 billion NPV at 10%, over 45% IRR, about $217 million of annual EBITDA, EBITDA margin above 70%, circa $280 million of capex, and a life of over 30 years. The company said it raised $14.6 million at 20p, has current cash burn of about $400,000 per month, and estimates $4 million to $4.5 million to complete the Phalaborwa DFS and related technical, environmental, and permitting workstreams. Guidance-wise, it expects the Phalaborwa DFS by the end of this year, financing work in parallel, FID targeted for the end of Q3 2027, early works and FEED in Q4 2027, full construction in 2028, and commissioning/production in late 2028 to Q1 2029; Uberaba is being targeted for production in 2030.

George Bennett’s message was that Rainbow has used the extra time to de-risk the process and improve the economics, not just to chase the original timeline. He said the company successfully produced a commercial mixed rare-earth hydroxide product at pilot scale, moved to a standard solvent-extraction route, and simplified the front-end flowsheet to reduce capex and operating risk. His tone was confident and dismissive of the idea that the delay is a setback, framing it instead as a better outcome for shareholders.

No CFO spoke on the call, but management discussed financials in detail. Bennett said the recent raise of $14.6 million gives Rainbow runway well into the end of 2027 and that current burn is about $400,000 per month, with total cash needs to finish the Phalaborwa DFS and associated work at $4 million to $4.5 million. He also emphasized that the Brazil deal carries no cash outlay for Rainbow beyond its IP contribution and 49% share of capex, and that the company expects a funding mix of about two-thirds debt and one-third equity for project finance.

Analysts focused on the timeline slip, the demand outlook for permanent magnets, a possible U.S. listing, and the level of cash needed before FID. Management said the delay came from abandoning the American chromatography route after it did not deliver claimed results, and that the pivot to solvent extraction actually reduced technical risk and improved the flowsheet. On demand, Bennett rejected substitution concerns, said permanent magnets remain the most efficient solution, and pointed to EVs, drones, eVTOLs, robotics, and defense as ongoing drivers; on a U.S. listing, he said it could help narrow the valuation discount but no timetable was given.